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postoperative computed tomography angiography
as criteria for no additional imaging up to 5 years
after endovascular aneurysm repair
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Objective: Intensive image surveillance after endovascular aneurysm repair is generally recommended due to continued risk
of complications. However, patients at lower risk may not beneﬁt from this strategy. We evaluated the predictive value of
the ﬁrst postoperative computed tomography angiography (CTA) characteristics for aneurysm-related adverse events as
a means of patient selection for risk-adapted surveillance.
Methods: All patients treated with the Low-Permeability Excluder Endoprosthesis (W. L. Gore & Assoc, Flagstaff, Ariz) at
a tertiary institution from 2004 to 2011 were included. First postoperative CTAs were analyzed for the presence of
endoleaks, endograft kinking, distance from the lowermost renal artery to the start of the endograft, and for proximal and
distal sealing length using center lumen line reconstructions. The primary end point was freedom from aneurysm-related
adverse events. Multivariable Cox regression was used to test postoperative CTA characteristics as independent risk
factors, which were subsequently used as selection criteria for low-risk and high-risk groups. Estimates for freedom from
adverse events were obtained using Kaplan-Meier survival curves.
Results: Includedwere 131 patients. Themedian follow-upwas 4.1 years (interquartile range, 2.1-6.1). During this period,
30 patients (23%) sustained aneurysm-related adverse events. Seal length <10mmand presence of endoleakwere signiﬁcant
risk factors for this end point. Patients were subsequently categorized as low-risk (proximal and distal seal length$10 mm
andno endoleak, n[62)orhigh-risk (seal length<10mmorpresenceof endoleak, orboth; n[69).During follow-up, four
low-risk patients (3%) and 26 high-risk patients (19%) sustained events (P < .001). Four secondary interventions were
required in three low-risk patients, and 31 secondary interventions in 23 high-risk patients. Sac growthwas observed in two
low-risk patients and in 15 high-risk patients. The 5-year estimates for freedom from aneurysm-related adverse events were
98% for the low-risk group and 52% for the high-risk group. For each diagnosis, 81.7 image examinations were necessary in
the low-risk group and 8.2 in the high-risk group.
Conclusions: Our results suggest that the ﬁrst postoperative CTA provides important information for risk stratiﬁcation
after endovascular aneurysm repair when the Excluder endoprosthesis is used. In patients with adequate seal and no
endoleaks, the risk of aneurysm-related adverse events was signiﬁcantly reduced, resulting in a large number of unnec-
essary image examinations. Adjusting the imaging protocol beyond 30 days and up to 5 years, based on individual
patients’ risk, may result in a more efﬁcient and rational postoperative surveillance. (J Vasc Surg 2013;57:1503-11.)The early survival beneﬁt of endovascular aneurysm the preferred strategy for treatment of patients with aortic
repair (EVAR) over open surgery has resulted in a gradual
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://dx.doi.org/10.1016/j.jvs.2012.11.085abdominal aneurysms (AAAs).1-3 The main drawback of
EVAR remains the durability of the procedure, with
frequent need of secondary intervention for continued
success.2,4-7 To assess treatment failure and ultimately
prevent death from rupture, intensive life-long postopera-
tive surveillance strategies are recommended, which
include at least annual computed tomography angiography
(CTA), duplex ultrasound (DUS) imaging, abdominal
radiography, or a combination of these.8
Intensive image follow-up strategies are not innocuous,
however. Contrast-induced nephropathy and radiation
exposure are worrisome factors when CTA is used as the
preferred strategy.9,10 Alternatively, DUS imaging is labo-
rious, window and operator dependent, and requires intra-
venous contrast to obtain comparable results.11 With both
imaging techniques, examinations and subsequent follow-
up visits are costly and involve signiﬁcant resource allocation,
which is only justiﬁable if patients are at risk of complications.1503
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tions, especially anatomic risk factors, have been studied
extensively, with fairly consistent results.12-15 However,
complications may ensue even in patients with anatomic
suitability. This additional risk may result from intraopera-
tive variables or vessel-graft interactions that cannot be
evaluated beforehand. The ﬁrst postoperative CTA may
provide valuable additional information and sharpen the
predictive capacity for adverse events during follow-up.
This, in turn, can help in patient selection, reserving the
intensive image follow-up protocols to patients at higher risk.
The purpose of this study was to evaluate the prog-
nostic capacity of the ﬁrst postoperative scan and identify
a subgroup of patients at very low risk of AAA-related
adverse events after EVAR.
METHODS
This study complies with the Declaration of Helsinki
on research ethics.
Study design. This single-institution retrospective
study was based on a prospectively kept database of AAA
patients treated by EVAR since 2000 at Erasmus University
Medical Center, Rotterdam, The Netherlands.
Patient population. From January 2000 until De-
cember 2011, 449 patients with aortoiliac aneurysms were
treated at our institution. For this study, only AAA patients
treated with the Low-Permeability (LP) Excluder Endo-
prosthesis (W. L. Gore and Assoc, Flagstaff, Ariz) were
included. Exclusion criteria were previous abdominal aortic
surgery or infectious aortic pathology. Patients treated until
December 2007 were also included in a recently published
study aimed at long-term results and morphologic analysis.16
All patients were assessed preoperatively using CTA and
entered the institutional follow-up protocol that included an
early postoperative CTA (typically before hospital discharge),
a CTA at 6 months and 1 year, and then CTAs yearly
thereafter.
Since 2007, the 6-month examination has been waived
and CTA surveillance replaced by DUS imaging in selected
patients considered at lower risk according to the treating
physician’s expectations in concurrence with the Clinical
Practice Guidelines of the European Society for Vascular
Surgery.8 Also, DUS imaging or noncontrast CTs were
performed as an alternative to CTA in patients with
impaired renal function.
Preoperative baseline characteristics included age, sex,
American Society of Anesthesiologists classiﬁcation, and
anatomic details. Intraoperative details were obtained
from operative records and included all intraoperative
complementary procedures. Subsequent information was
obtained from patient records, and all AAA-related compli-
cations and secondary interventions were noted. Cause of
death was obtained for patients who died during follow-up.
Image acquisition and analysis. CTA image acquisi-
tion was performed according to institutional protocols for
EVAR using a 16-slice or 64-slice Brilliance CT scanner
(Philips Medical Systems, Best, The Netherlands). Per pro-
tocol, collimation is 16 mm 1.5 mm or 64mm 0.6 mm,and pitch is 1.15 or 1.2, for 16-slice and 64-slice,
respectively. Field of view is the entire abdomen, and the
window is set at 350/150 with an increment of 1.0 mm.
Radiation parameters are 120 kVp and 150 mA. Intra-
venous nonionic iodixanol contrast (Visipaque 320; GE
Healthcare, Buchler GmbH & Co KG, Braunschweig,
Germany) is administered at a dose of 120 mL, using
bolus triggering in the juxtadiaphragmatic descending
aorta at a threshold of 100 Hounsﬁeld units over the
baseline. Detailed preoperative and postoperative mea-
surements were available in our institutional database.
In addition, all ﬁrst postoperative CTA were reanalyzed
using manually generated center lumen line reconstruc-
tions of the proximal and distal sealing zones using post-
processing 3Mensio Vascular 4.2 software (3Mensio
Medical Imaging BV, Bilthoven, The Netherlands). For
the proximal seal, markers were placed in the center of
the lumen using axial slices starting at the superior mesen-
teric artery and at every 2 mm progressing downward until
the ﬂow divider. For the distal seal, markers were placed
starting distal to the end of the endograft limb and pro-
gressing upward until the aortic bifurcation. The sealing
length was considered to be the distance where the entire
circumference of the aortic and iliac vessel walls and the
endograft are completely adjacent. This can be easily veri-
ﬁed using the reconstructed axial slices and the distance
measured in the stretched-view window (Fig 1). One
vascular surgeon with experience in image analysis
(F.B.G.) performed all of the measurements.
The duration of each CTA analysis was typically <5
minutes. Intraobserver variability was tested for a sample
of 30 patients, with very good agreement (Pearson correla-
tion coefﬁcient, 0.940; P < .001). A second observer
(K.v.L.) repeated these measurements, without signiﬁ-
cant variability (Pearson correlation coefﬁcient. 0.938;
P < .001). Bland-Altman plots were created for intraob-
server and interobserver variability (Fig 2).
Deﬁnitions. Anatomic suitability was deﬁned accord-
ing to the instructions for use for the Excluder Endopros-
thesis.17 A patient was considered to have suitable anatomy
if all of the following criteria were met: neck diameter,
19 to 28 mm; neck length, >15 mm; thrombus or calci-
ﬁcation in <50% of the aortic circumference, and neck
angulation <60.
Oversizing was determined retrospectively according to
the following formula: (implanted main-body diameter e
reference neck diameter in ﬁrst 15 mm of intrarenal
neck)/reference neck diameter in ﬁrst 15 mm of infrarenal
neck. Insufﬁcient oversizing was considered if <10%.
Additional intraoperative procedures were classiﬁed as
any additional act performed intraoperatively, not part of
the standard endograft implantation, such as proximal
cuff or giant Palmaz stent placement, or iliac balloon angio-
plasty or stenting.
Sufﬁcient postoperative seal was considered if a min-
imum seal length of 10 mm was present proximally and
distally. This 10-mm threshold was based on the manu-
facturer’s instructions for use (minimum proximal neck of
Fig 1. Method for determining seal length using center lumen line reconstruction. A, Reconstructed axial slice shows
adequate seal, 2 mm below the renal arteries, with good wall-graft apposition in the entire vessel circumference. B,
Same patient, 30 mm below the renal arteries, shows inadequate seal. C, Length of adequate proximal seal, measured in
stretched view.
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for a margin of error in the proximal deployment of
5 mm.16
Early postoperative endoleak was considered as type I,
II, III, or undetermined endoleaks observed on the ﬁrst
postoperative CTA.
Deployment accuracy was measured as the distance
from the lower edge of the lowermost renal artery and
the point where the entire circumference of the aortic
wall is covered by the endograft. Suboptimal deployment
was deﬁned as positioning of the proximal segment markers
of the endograft >5 mm below the optimal position,
immediately below the lowermost renal artery. Because
distance measurements on intraoperative angiography
were unreliable, the distance from the lowermost renal to
the endograft on the ﬁrst CTA was used as a surrogate.
Endograft kinking was considered present if some
part of the device displayed a sharp angular image >90,
which was retrospectively identiﬁed and consensual after
examination by two vascular surgeons experienced in
EVAR.
Sac growth was deﬁned as an increase in diameter >5
mm compared with the ﬁrst postoperative examination,
according to the reporting standards for EVAR.18 Inversely,
sac shrinkage was considered as a reduction in diameter
>5 mm.
AAA-related adverse events were deﬁned as a composite
of the following: occurrence of type Ia, type Ib, type III, or
undetermined type endoleaks on postoperative examina-
tions, AAA growth >5 mm in diameter during follow-up,
migration>10mm, device failure, AAA-related death, post-
implantation AAA rupture, or any AAA-related secondary
intervention.18
End points. The primary study end point was freedom
from AAA-related adverse events. Individually, elementsof this composite end point were analyzed separately as
secondary end points.
Statistical analysis. To assess the importance of
different variables obtained from the ﬁrst postoperative
CTA (seal length, presence of endoleak, endograft kinking,
and deployment accuracy), univariable Cox regression
analysis was performed. The degree of oversizing was also
tested as a possible confounder. Signiﬁcant variables were
then entered in a multivariable model to test for interaction
and used as selection criteria for inclusion in a high-risk or
low-risk group. Baseline and intraoperative characteristics,
as well as distribution of events during follow-up, were
compared between groups using count and percentages.
Categoric variables are presented as count and percentage
and were compared with Pearson c2 tests. Continuous
variables are presented as mean and standard deviation and
were compared using Student t-tests or are presented as
median and interquartile range (IQR) and were compared
with Mann-Whitney U tests for nonparametric distribu-
tions. A Kaplan-Meier survival estimate was calculated for
freedom from AAA-related adverse events. Estimates for
low-risk and high-risk groups were compared using the
log-rank (Mantel-Cox) test of equality. Differences were
considered signiﬁcant if P < .05. Statistical analysis was
performed using IBM SPSS Statistics 20 software (IBM
Inc, Chicago, Ill).RESULTS
From July 2004 to December 2011, 145 AAA patients
were treated with the LP Excluder endoprosthesis at our
institution. The study excluded 14 patients: seven had
previous aortic open reconstruction, three were mycotic
aneurysms, two patients with ruptured AAAs died before
a postoperative CTA could be performed, and one was
Fig 2. Bland-Altman plots show (top) intraobserver and (bottom)
interobserver variability on neck length measurements.
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patients were available for analysis.
The follow-up duration of this cohort was a median 4.1
years (IQR, 2.1-6.1; maximum, 8.1 years). During this
period, 30 patients (23%) sustained AAA-related adverse
events. The median interval between the index operation
and the ﬁrst postoperative CTA was 2.0 days (IQR, 1-9
days) for the low-risk group and 3.5 days (IQR, 2-17 days)
for the high-risk group (P ¼ .081). In 10 patients (four in
the low-risk group), the CTAwas delayed>30 days because
of concerns about renal function deterioration.
Univariable analysis of possible risk factors for AAA-
related adverse events revealed length of seal <10 mm
and presence of endoleak on the ﬁrst postoperative CTA
were signiﬁcant. These remained signiﬁcant after multivari-
able testing (Table I). These ﬁndings were used to divide
patients into a low-risk group (proximal and distal seal
length $10 mm and no endoleak) and a high-risk group
(with insufﬁcient seal or presence of endoleak, or both).
Baseline characteristics are detailed in Table II, and the
details of inclusion criteria for the high-risk group are pre-
sented in Table III.Four patients (3%) in the low-risk group and 26 (19%)
in the high-risk group sustained AAA-related adverse
events (P < .001) during the follow-up. Four secondary
interventions were required in three patients in the low-
risk group, and 31 secondary interventions were required
for 23 patients in the high-risk group. Sac growth was
observed in two low-risk patients (3%) and in 15 (22%)
high-risk patients. No migration or device failure was
observed in either group. All AAA-related adverse events
are detailed in Table IV.
Kaplan-Meier estimates for freedom from AAA-related
adverse events were signiﬁcantly different between the two
groups (P < .001, Fig 3), with 5-year estimates of 98% for
the low-risk group and 52% for the high-risk group.
Four patients in the low-risk group sustained AAA-
related adverse events: one patient was converted to open
repair due to aortic rupture as a consequence of endograft
infection, 2.11 years after EVAR. No signs of infection
were present in the 2-year CTA, and sac shrinkage was
noted. Unlike the previous cases, this operation resulted
from an additional investigation prompted by the presence
of symptoms and not as a result of an image ﬁnding.
One patient was diagnosed with sac growth after 5
years, in the absence of identiﬁable endoleak, and was
treated by relining the endograft. This treatment was
unsuccessful in arresting growth, and a type Ib endoleak
became evident 1 year later, which was likely the original
cause of growth.
One patient required implantation of an iliac extension
(nearly 7 years after EVAR) due to progression of disease
and loss of distal seal length.
Lastly, one patient was diagnosed with growth 5 years
postoperatively, after a period of shrinkage. This patient
was managed conservatively until the end of follow-up.
Details of secondary interventions occurring in the low-
risk group are provided in Table V.
In the high-risk group, only patients with type I endo-
leaks, persistent type II endoleaks associated with sac growth,
and progressively shorter seal required an intervention.
During the study period, this patient cohort was
subject to intensive periodic imaging, mostly using con-
trasted examinations (Table VI). For each diagnosis of an
AAA-related adverse event over the course of follow-up,
81.7 image examinations had to be performed in the
low-risk group and 8.2 in the high-risk group. Imaging
was necessary to identify three (75%) of the AAA-related
adverse events in the low-risk population, but all occurring
after 5 years. In the high-risk group, imaging identiﬁed 25
of 26 (96%) of all AAA-related complications.
DISCUSSION
Complications and secondary interventions are
frequent after EVAR, and intensive image follow-up is
considered mandatory to allow for timely elective treat-
ment of potentially fatal complications that course silently
until an acute event occurs, usually rupture or occlusion.8
Our study suggests, however, that an identiﬁable subgroup
of patients may not beneﬁt from image follow-up for
Table II. Baseline characteristics
Variablea
Low risk
(n ¼ 62)
High risk
(n ¼ 69) P
Age, years 70.9 6 7.7 73.4 6 7.3 .058
Female 4 (6) 9 (13) .25
AAA diameter, mm 63.3 6 13.8 64.0 6 15.5 .8
Neck diameter, mm 24.1 6 2.5 24.4 6 3.0 .63
Neck length, mm 32.9 6 14.2 32.4 6 15.3 .85
ASA class III or IV 34 (55) 30 (43) .22
Symptomatic/ruptured 11 (18) 10 (14) .64
Angulation
Suprarenal 21 6 17 24 6 17 .41
Infrarenal 34 6 17 37 6 21 .32
Neck thrombus 25 (40) 20 (29) .2
Neck calciﬁcation 0 0 .
Iliac stenosis 4 (6) 8 (12) .37
Iliac tortuosity 14 (23) 18 (26) .69
Iliac aneurysms 18 (29) 20 (29) >.99
Anatomic suitability 50 (81) 45 (65) .053
AAA,Abdominal aortic aneurysm;ASA,AmericanSocietyofAnesthesiologists.
aContinuous data are presented as the mean 6 standard deviation and
categoric data as number (%).
Table I. Univariable and multivariable analysis of ﬁrst postoperative CTA variables associated with AAA-related adverse
events during follow-up (Cox regression).
Variable No. (%)
Univariable Multivariable
HR (95% CI) HR (95% CI)
Seal length <10 mm 38 (29) 4.32 (2.08-8.98) 3.89 (1.86-8.15)
Endoleak on ﬁrst postoperative CTA 48 (37) 2.61 (1.27-5.39) 2.19 (1.06-4.54)
Endograft kinking 3 (2) 0.05 (0-5981.2) .
Suboptimal deployment 38 (29) 1.23 (0.58-2.64) .
Oversizing <10% 35 (27) 0.53 (0.21-1.30) .
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; CTA, computed tomography angiography; HR, hazard ratio.
Table III. Details of the inclusion criteria of the high-
risk group
Inclusion criteria
No. (%)
(n ¼ 69)
Seal length <10 mm 38 (55)
Short proximal seal 18 (26)
Short distal seal 22 (32)
Endoleak 48 (70)
Type Ia 4 (6)
Type Ib 2 (3)
Type II 37 (54)
Type III 0 (0)
Type undetermined 5 (7)
Seal length <10 mm and endoleak 17 (25)
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similar to open surgery.
Intensive follow-up imaging may have deleterious
effects for patients and health care providers alike. For
patients monitored with CTA, radiation exposure and
contrast nephropathy are important associated factors
that should not be overlooked.9,10,19 Alternatively, DUS
imaging is operator-dependent, laborious, and requires
intravenous contrast enhancement to achieve comparable
sensitivity.11,20 Whichever method is used, postoperative
image surveillance is costly, requires resource allocation,
and may negatively affect a patient’s well-being.21A recent
survey study from the United Kingdom revealed large
heterogeneity in surveillance protocols adopted by expert
centers.22 This uncertainty regarding the optimal surveil-
lance program reﬂects the paucity of evidence regarding
risk stratiﬁcation.
Preoperative anatomic features have beenwell character-
ized as risk factors for adverse outcome after EVAR.12-15
However, a good proximal or distal landing zone does not
guarantee an adequate seal. As an example, it is possible
that unintentional low deployment might turn a long prox-
imal neck into a short proximal seal. This is of particular
importance in patients with neck angulation, where thedistortion of anatomy induced by the deployment
systems and parallax error frequently result in oblique
positioning of the top stent with a much shorter sealing
zone than anticipated. Precise measuring of seal length
can be performed quickly and easily using center lumen
line reconstruction.
The effect of intraoperative details and on-table
imaging on secondary intervention after EVAR has also
been investigated. Karthikesalingam et al23 identiﬁed
higher risk for patients requiring intraoperative adjuncts
and lower risk for those undergoing intraoperative multi-
planar CTA. They suggest that these ﬁndings may serve
as selection criteria for stricter or more “relaxed” imaging
follow-up. Like ours, this study relied on the absence of
endoleak and adequate sealing zones for prediction of
complications. Because intraoperative adjuncts do not
always increase risk and on-table CTA is not widely avail-
able, we opted to use standard postoperative CTA and
postprocessing software for assessment. We believe this
approach provides a more applicable and reliable means
of monitoring the end result of EVAR procedures.
The concept of using early postoperative information
for risk prediction is not novel. Sternbergh et al21 showed
that freedom from endoleak at 1 month was highly predic-
tive of reduced aneurysm-related morbidity. As a result,
they proposed a simpliﬁed surveillance program that
excluded the 6-month examination and replaced CTA by
DUS imaging after the ﬁrst year. Adaptations of this
scheme have been widely accepted in clinical practice.8
Two studies also identiﬁed early postoperative endoleaks
Table IV. Events during follow-up
Variable
Low risk
(n ¼ 62),
High risk
(n ¼ 69),
PNo. (%) No. (%)
AAA-related adverse events,
patients
4 (6) 26 (38) <.001
Secondary intervention, events 4 31 <.001
Proximal stent/cuff 0 9
Limb extension 2 11
Coil/glue embolization 0 3
Relining 1 1
Conversion to open repair 1 3
Conversion to aortouniiliac 0 1
Open/laparoscopic fenestration 0 1
Thrombolysis and iliac PTA 0 2
Migration 0 0 .
Device failure 0 0 .
Endoleak during follow-up 0 (0) 38 (44) <.001
Type Ia - 4
Type Ib - 2
Type II - 27
Type III - -
Type undetermined - 5
Sac behavior .007
Growth 2 (3) 15 (22)
Stability 25 (40) 25 (36)
Shrinkage 35 (56) 29 (42)
AAA, Abdominal aortic aneurysm; PTA, percutaneous transluminal
angioplasty.
Fig 3. Kaplan-Meier survival curves show freedom from secondary
abdominal aortic aneurysm (AAA) intervention in low-risk and
high-risk patients during follow-up after endovascular aneurysm
repair (EVAR). SE, Standard error.
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the basis of absence of endoleak and adequate seal zones
on the ﬁrst postoperative CTA is a less speciﬁc but more
sensitive method than using endoleak presence alone, as
our study demonstrates.
A proportion of patients in our study were considered
high risk due to identiﬁcation of a type II endoleak. If de-
tected, these mandate intensive image surveillance because
of the risk of sac growth and, ultimately, rupture.26-28
Detection of these endoleaks using CTA is relatively insen-
sitive, however, as demonstrated by studies using magnetic
resonance angiography and blood-pool agents.29,30 Despite
this limitation, a much higher proportion of patients prog-
ress to sac growth when type II endoleaks are detected
This suggests that the method is still applicable as
a predictor.31 Also, speciﬁcity of type II endoleak detection
has been questioned, because many are reportedly misinter-
preted type I or III endoleaks.32 This adds strength to the
argument of including type II endoleaks as a criterion for
high-risk inclusion.
Within the ﬁrst 5 years, only one AAA-related adverse
event occurred in the low-risk group.33-35 This complica-
tion resulted from infection, which was not evident on
routine CTAs. As such, for our low-risk patient group,
the extensive follow-up did not seem to add signiﬁcant
beneﬁt up to 5 years. After 5 years, three additional events
occurred in low-risk patients. Two had progressively short-
ened distal sealing caused by iliac dilatation. The progres-
sion of disease can be expected many years after EVAR,36
and continued surveillance in patients with a prolongedlife expectancy is still obligatory, just like in open surgery.
The last patient was identiﬁed as having sac growth after
a period of shrinkage. The cause of growth could not be
determined, and the patient remained under close
surveillance.37
In the low-risk group, 82 image examinations had to
be performed for every identiﬁed AAA-related adverse
event. A cost-beneﬁt analysis is beyond the scope of this
study, but this alarmingly high rate of examinations
required casts doubt on the beneﬁt for patients and must
be acknowledged. Dias et al38 reported similar ﬁndings.
Over a median of 54 months, <10% of their cohort of
279 patients actually beneﬁted from CTA surveillance.38
Most secondary interventions performed were preven-
tive (preceding complications), even in high-risk patients.
Of 31 interventions, only six patients had a demonstrated
type 1 endoleak, and no ruptures occurred. Moreover, all
secondary procedures in the high-risk group were elective.
These ﬁndings, in line with previously published data on
outcome of secondary interventions,39 reinforce the impor-
tance of continued image surveillance for this group.
The results of this study suggest that a risk-stratiﬁed
postoperative surveillance protocol could be followed for
patients treated with the Excluder endoprosthesis (Fig 4).
In high-risk patients, standard annual CTA is advised, with
DUS imaging an alternative for selected patients with
impaired renal function or favorable sac remodeling. For
low-risk patients, imaging up to 5 years would only be per-
formed upon clinical suspicion and not for surveillance
purposes. This way, the follow-up strategy for low-risk
EVAR patients would not differ signiﬁcantly from the
Table V. Detailed analysis of adverse events in the low-risk group
Event Intervention
Time to
event, years
Endoleak
presence
Loss of
seal Outcome Follow-up, years
Endograft infection
with rupture
Open conversion 2.11 No No Postoperative death 2.11
Relining Sac growth 5.01 No No Persistent growth, later identiﬁed type Ib
endoleak treated with limb extension
7.46
Sac growth None 5.31 No No Continued sac growth 6.31
Limb extension Short iliac seal 6.81 No Yes Successful 7.21
Table VI. Analysis of postoperative image surveillance
Variablea
Low-risk High-risk
P(n ¼ 62) (n ¼ 69)
Total follow-up, years 4.0 (1.7-6.1) 4.2 (2.2-6.0) .42
Total exams performed before ﬁrst event or end of follow-up 245 205
CT angiography 183 170
DUS imaging 55 32
Noncontrast CT 7 3
Exams per patient before ﬁrst event or end of follow-upb 3.95 6 2.45 2.97 6 2.27 .019
AAA-related adverse events identiﬁed from image exams 3 (7) 25 (33) <.001
Exams needed for each AAA-related adverse event identiﬁed 81.7 8.2
AAA, Abdominal aortic aneurysm; CT, computed tomography; DUS, duplex ultrasound imaging; IQR, interquartile range.
aContinuous data are presented as median (IQR) or mean 6 standard deviation and categoric data as number (%).
bExcluding preoperative and ﬁrst postoperative CT angiography.
Fig 4. Possible follow-up imaging surveillance with computed
tomography angiography (CTA) and duplex ultrasound (DUS)
imaging for patients treated with the Excluder endoprosthesis.
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annual CTA or DUS imaging seem advisable due to the
risk of late complications as a result of disease progression.
Because this is only a preliminary study, this proposed
scheme should not be adopted for clinical care before the
results can be conﬁrmed in large, prospective series.
The retrospective, single-center nature of this study is
a limitation that must be acknowledged. Also, selection
of patients according to the type of device implanted may
be a source of bias and restricts generalization. However,institutional experience with the Excluder endoprosthesis
was predominant, and only small numbers of patients
were treated with other devices for many years. Moreover,
most other devices used before 2008 are no longer
commercialized. For the Excluder endograft, on the other
hand, there is long-term follow-up, and the device is ex-
pected to be available for years to come. From 2008,
many patients at our center were treated with a fourth-
generation Endurant endoprosthesis (Medtronic Endovas-
cular, Santa Rosa, Calif). Because follow-up duration is
very restricted for this group and extrapolation of future
results is impossible, we opted not to include them.
The time between the index operation and the ﬁrst
postoperative CTA was not standardized, which could
result in variability. However, this would likely affect
both groups equally. The distribution of the time to the
ﬁrst CTA was similar between groups, but the median
differed by 1.5 days. This difference did not reach statistical
signiﬁcance, perhaps due to sample size, but should be
assumed as a limitation.
Lastly, we cannot ensure that the distance from the
lowermost renal artery to the start of the graft remained
the same after deployment until the CTA was performed.
Because migration is possible during this interval, true
deployment accuracy is only an approximation and may
not reﬂect the true intraoperative result in all cases.
CONCLUSIONS
The present study suggests that the ﬁrst postoperative
CTA after EVAR can be used to stratify for the risk of
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1510 Bastos Gonçalves et al June 2013AAA-related adverse events, based on the presence of
endoleak and the length of proximal and distal seal. On
one hand, roughly half of patients in our population were
considered low risk, and imaging surveillance up to 5 years
could have been waived, making their follow-up similar to
patients undergoing open surgical repair. On the other
hand, the results emphasize the need for close surveillance
of patients at higher risk of complications. This concept
requires validation with larger cohorts and a mixed sample
of devices before it leads to a signiﬁcant change in practice
but highlights the necessity to re-evaluate current “one-
size-ﬁts-all” surveillance protocols.
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